Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (1358)	8/10/2005 2:36:49 PM
From: Jibacoa	Respond to of 3722

CURE, Yes it is very risky to stay long at the time of revenue & earnings reports>.<G> CURE's 2ndQ results were not good.<g> Although the revenues were $71.6M up 11% from the $64.4M last year,the loss increased to $0.37/shr share, and its "ratings" were cut by SS and S&P <g> The stock dropped through the "support" from its Hs of May, June & July at the 2.70 level but it is still holding above its June 27 L of 1.82 and its April 27 L of 1.37 <g> (Will see if it can stay above its intraday L of 2.38) The stock is going to need some time building a base before trying to close today's downgap above the 2.62 level.<g> bigcharts.marketwatch.com Bernard